Compare Neurocrine Biosciences Inc (NBIX) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Abrdn Physical Platinum Shares ETF trades at $14.8. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | PPLT | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $180.55 | $25.23 |
52-Week Low | $123.10 | $11.78 |
Enterprise Value | $16.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.47, down 0.21% on the day, amid a predominantly bearish technical signal with moving averages indicating strong selling pressure. The fund, which holds physical platinum, has seen significant volatility, with recent news highlighting its underperformance compared to gold and silver. A 10-for-1 stock split is scheduled for May 2026, which will adjust the share count without altering the fund's net asset value.
The outlook for PPLT is cautious, with technical indicators leaning bearish and sentiment mixed after a substantial rally. Investment opportunity hinges on a potential catch-up trade if platinum gains favor, but risks include commodity price swings and the ETF's lack of dividends, which may deter income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
